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Abstract— The CDOI outcome measure – a patient-reported 
outcome (PRO) instrument utilizing direct client feedback – 
was implemented in a large, real-world behavioral healthcare 
setting in order to evaluate previous findings from smaller 
controlled studies.  PROs provide an alternative window into 
treatment effectiveness based on client perception and 
facilitate detection of problems/symptoms for which there is no 
discernible measure (e.g. pain).  The principal focus of the 
study was to evaluate the utility of the CDOI for predictive 
modeling of outcomes in a live clinical setting.  Implementation 
factors were also addressed within the framework of the 
Theory of Planned Behavior by linking adoption rates to 
implementation practices and clinician perceptions.  The 
results showed that the CDOI does contain significant capacity 
to predict outcome delta over time based on baseline and early 
change scores in a large, real-world clinical setting, as 
suggested in previous research.  The implementation analysis 
revealed a number of critical factors affecting successful 
implementation and adoption of the CDOI outcome measure, 
though there was a notable disconnect between clinician 
intentions and actual behavior.  Most importantly, the 
predictive capacity of the CDOI underscores the utility of 
direct client feedback measures such as PROs and their 
potential use as the basis for next generation clinical decision 
support tools and personalized treatment approaches. 
Keywords- Data Mining; Patient-Reported Outcomes; CDOI; 
Implementation; Electronic Health Records; Decision Support 
Systems, Clinical; Theory of Planned Behavior 
I.  INTRODUCTION 
Recent years have seen the proliferation of the concepts 
of patient-reported outcomes (PROs) and client feedback 
throughout the healthcare and behavioral healthcare spheres.  
Research has begun to illuminate their utility on the 
effectiveness of clinical treatment across multiple disorders 
and diseases, including depression, schizophrenia, diabetes, 
cancer, and speech problems, among others [1-5].  The basic 
concept is that utilizing outcomes and/or feedback directly 
from the patient, rather than filtered through the perspective 
of the clinician, can provide meaningful information around 
a patient’s current status, progress, and prognosis.  
More specifically, PROs have been suggested to benefit 
clinical practice via 1) facilitating the detection of 
overlooked problems, including some symptoms for which 
there is no discernible measure (e.g. pain), 2) providing an 
alternative window into treatment effectiveness that still 
utilizes standardized measures, 3) potentially improving 
patient-clinician communication, and 4) being unaffected by 
inter-rater reliability [1,6].  On the other hand, PROs have 
been criticized for 1) being too lengthy and burdensome on 
clinical workflow, and 2) the skepticism surrounding their 
clinical meaning and relevance [6].  Beyond this, even if 
PROs have no direct negative effects, their use may preclude 
the use of other, more meaningful measures given the limited 
clinical time available for outcomes collection [7]. 
CDOI (Client-Directed Outcome Informed) is a PRO 
developed by Miller et al. [8].  It was developed with the 
specific purpose of providing a valid yet brief outcome 
measurement system that could fit practically into real-world 
clinical practice.  The CDOI is a session-based measure, 
collected electronically at every visit.  It is comprised of two 
ultra-brief scales comprising 4 questions each – ORS (a 
measure of clinical symptomology and functioning) and SRS 
(a measure of therapeutic alliance).  Previous research has 
shown ORS to compare favorably with other, longer 
outcome measures such as OQ45 [9,10], as well as the SRS 
comparing favorably to other, longer measures of therapeutic 
alliance such as the HAQ-II [11].  In concert with findings 
from other PRO studies, evaluation of the CDOI has shown 
that it can improve clinical outcomes [8,12].   
The principal focus of the study was on evaluating the 
utility of the CDOI for predictive modeling of outcomes in a 
live clinical setting.  The question exists what utility such an 
approach may hold with respect to clinical decision support 
(CDSS) recommendations, particularly a data-driven 
approach to CDSS that relies on data from live clinical 
systems and artificial intelligence algorithms that “learn” 
over time.  Electronic health records themselves are only a 
first step.  Techniques such as predictive modeling and data 
mining can detect patterns in the data that can be applied to 
new clients when they walk in the door, for example 
providing recommendations to clinicians about the treatment 
options most likely to be effective for a specific individual.  
This is, in essence, an individualized form of practice-based 
evidence.  Another term for this is “personalized medicine” 
[13,14].  PROs and client feedback can play an important 
role in this sort of individualized approach [5]. 
Prior work in this area has primarily addressed the utility 
of genetic data to inform individualized care.  However, it is 
likely that the next decade will see the integration of multiple 
sources of data – genetic, clinical, socio-demographic – to 
build a more complete profile of the individual, their 
inherited risks, and the environmental/behavioral factors 
associated with disorder and the effective treatment thereof 
[15].  Indeed, we already see the trend of combining clinical 
and genetic indicators in prediction of cancer prognosis as a 
way of developing cheaper, more effective prognostic tools 
[16-18].  
PROs and client feedback fit into this larger paradigm 
around personalized medicine and clinical decision support 
technology (CDSS).   However, evidence shows only a small 
minority of clinicians report collecting outcomes in any form 
[19].  Bickman [20] addressed these issues, noting that 
“currently everyone but the client appears to benefit from not 
having a measurement feedback system” (pp.1115).  States 
and funders can claim they are providing for the needs of 
their citizens without worrying about the effectiveness (or 
ineffectiveness) of the resources spent.  Provider 
organizations can justify their use of funds by claiming they 
use “evidence-based” practices.  Clinicians and supervisors 
can evaluate their performance based on their own 
perceptions rather than actual data [20].  Establishing the 
utility of PROs and client feedback for making actual 
treatment decisions is critical to addressing such realities. 
A secondary focus of the study was to examine the role 
of implementation factors within the framework of the 
Theory of Planned Behavior (TPB) [21] by linking adoption 
rates to implementation practices and clinician perceptions.  
This is a critical topic in understanding utilization of 
technology, research innovations, outcomes assessments 
(including PROs such as CDOI), and the like in real world 
settings [22-25].  Good technology that goes unused is of 
questionable success.  There is still a need for better 
understanding of multi-pronged, flexible yet replicable 
implementation strategies and barriers thereof [26,27].  
II. METHODS 
A. Setting and Data 
The CDOI was implemented at Centerstone, the largest 
community-based (outpatient clinic) mental healthcare 
provider in the United States seeing over 75,000 distinct 
individuals a year across 130 clinic locations in Indiana and 
Tennessee.  Centerstone Research Institute is an arm of 
Centerstone devoted to integrating evidence and practice, 
conducting clinical research, developing clinical decision 
support tools, and building new healthcare informatics 
technologies, among other goals.  Centerstone has a fully 
functional electronic health record (EHR) that maintains 
virtually all relevant patient records.  Its clinical services 
operate under a mixture of both fee-for-service and case rate 
payment methodologies, including Medicare, Safety Net 
(Tennessee-sponsored health insurance for the population of 
seriously mentally ill who are ineligible for Medicaid), three 
distinct Medicaid payers (due to state subcontracting) with 
different sets of rules, a variety of Commercial payers, as 
well as an assortment of “other” payers such as county 
subsidies, DCS (Tennessee Dept. of Children Services), 
federal probation funds, and grants. 
Approximately 150 clinicians were selected for inclusion 
in a 6-month pilot study from March 2010 thru August 2010.  
These included clinicians both in adult outpatient therapy as 
well as intensive in-home case management for children.  
For purposes of this analysis, data was limited to that 
collected for adults and adolescents over the age of 13 who 
received at least some therapy.  The CDOI was integrated 
into the EHR and collected on a per session basis.  As often 
occurs in real clinical practice, the CDOI was not always 
collected with fidelity at every single time point, and patients 
had the option to skip the ORS or SRS at any point if they so 
chose.  The ORS was collected at the beginning of each 
session via a slider bar (scale 0-10) directly on the screen 
that the client could manipulate, in relation to each of the 
four questions that comprise the ORS scale [8].  The SRS 
was similarly collected, but at the end of each session via a 
slider bar (scale 0-10) directly on the screen that the client 
could manipulate, in relation to the four questions that 
comprise the SRS scale [8].  Furthermore, clients were 
identified as either “new” or “old” based on whether they 
had been seen within 90 days prior of the baseline CDOI at 
any Centerstone treatment facility or program. 
For purposes of the data mining analysis, data was 
limited to those patients who received both a baseline CDOI 
and 3rd visit CDOI (based on previous “early change” 
findings, see the Results section), as well as having an 
additional CDOI at some point between the 5th visit and 
10th visit (defined as the “final” CDOI).  As such, all 
patients included in the sample were essentially examined 
based on their first 10 visits, which generally equates to a 3-4 
month time period.  The final sample was n=714 (n=253 for 
new patients only).  On average, they received 7.2 visits 
during the 6 month pilot, with an average length of stay of 
115 days (defined as baseline to final; patients may have 
continued to receive services outside the scope of the CDOI 
analysis). 
 
B. Data Analysis 
Data was pulled nightly from the electronic health record 
and loaded into a data warehouse (DW) specifically for 
answering research and analytical questions.  The DW also 
served as the basis for reporting and clinical feedback as 
specified in the implementation section below [14].  
Subsequently, data was loaded into KNIME (Version 2.3.1) 
[28], an advanced data mining, modeling, and statistical 
software package.  Data mining typically follows a standard 
process flow that can be broken into a number of main steps: 
data preparation, feature selection, model construction, and 
model evaluation.  It should be noted that not all of these 
steps are performed all the time – for instance one may build 
models without any feature selection in order to evaluate the 
effect of feature selection on a particular dataset.  Below, 
these steps are briefly outlined in the context of the current 
study; a more comprehensive overview of specific data 
mining strategies and methodologies can be found in any of 
a number of resources on the subject [29,30]. 
The primary analysis focused on clinical outcomes as 
measured by the change in ORS scores over time (research 
questions #1 and #2).  The primary question was whether 
clients would obtain average or better outcome delta (change 
over time) from baseline to final visit (or vice versa, worse 
outcome delta).  As such, the target variable (ORS delta 
final) was discretized into a binary variable of plus/minus the 
mean (equivalent to an equal bins classification approach).  
The consequences and assumptions of reduction to a binary 
classification problem are addressed in Boulesteix et al. [18], 
noting that the issues of making such assumptions are 
roughly equivalent to making such assumptions around 
normal distributions.  All predictor variables (shown in Table 
I) were z-score normalized.  Subsequently, all predictor 
variables were either 1) not discretized (labeled “Bin 
Target”), or 2) discretized via CAIM (Class-Attribute 
Interdependence Maximization).  CAIM is a form of 
entropy-based discretization that attempts to maximize the 
available “information” in the dataset by delineating 
categories in the predictor variables that relate to classes of 
the target variable.  By identifying and using patterns in the 
data itself, CAIM has been shown to improve classifier 
performance [31]. It should be noted that not all models are 
capable of handling both discretized and continuous 
variables, and thus both methods were not applied to all 
modeling methods.  Additionally, some methods, such as 
certain kinds of neural networks or decision trees, may 
dynamically convert numeric variables into binary or 
categorical variables as part of their modeling process.  As 
such, even when no pre-discretization was performed, it may 
have occurred within the modeling process itself.  It should 
also be noted that practically all clients during the pilot 
received therapy services, which effectively excised all the 
q_therapy variables, including specific individual and group 
ones, from the analysis due to lack of variance. 
TABLE I.  VARIABLE LIST 
Variable Description
bl_ors Baseline ORS
bl_srs Baseline SRS
third_delta_ors ORS delta from baseline to third visit
third_delta_srs SRS delta from baseline to third visit
gender Gender of client
diag_cat Primary Diagnostic Category (e.g. Mood, Anxiety, Substance Abuse) 
age Age of client
payor_grp Payor Group (e.g. Medicaid, Medicare, Commercial, etc.)
county County of primary clinic location of client
region_type Urban or Rural
q_case_mgmt_bin Binary (1/0) if client received any Case Mgmt services
q_medical_bin Binary (1/0) if client received any Medical services
q_therapy_bin Binary (1/0) if client received any Therapy services
q_ind_therapy_bin Binary (1/0) if client received any Individual Therapy services
q_grp_therapy_bin Binary (1/0) if client received any Group Therapy services
state State of primary clinic location of client
final_delta_ors Target (Dependent) variable, ORS delta from baseline to final  
 
Multiple models were constructed on the dataset to 
determine optimal performance using both native, built-in 
KNIME models as well as models incorporated from WEKA 
(Waikato Environment for Knowledge Analysis; Version 
3.5.6) [30]. Models were generally run using default 
parameters, though some experimentation was performed.  
Of note, decay was set to true for MP Neural Networks, 
max_parents was set to 3 for Bayesian Network-K2, and 
number of nearest neighbors was set to 3 for K-Nearest 
Neighbors.  Models tested included Naïve Bayes [30], HNB 
(Hidden Naïve Bayes) [32], AODE (Aggregating One-
Dependence Estimators) [33], Bayesian Networks[30], 
Multi-layer Perceptron neural networks [30], Random 
Forests [34], J48 Decision Trees (a variant of the classic 
C4.5 algorithm) [35], Log Regression, and K-Nearest 
Neighbors [36].  Additionally, ensembles were built using a 
combination of Naïve  Bayes, Multi-layer Perceptron neural 
network, Random Forests, K-nearest neighbors, and logistic 
regression, employing forward selection optimized by AUC 
(area under the curve) [37].  Voting by committee was also 
performed with those same five methods, based on 
maximum probability [38].  Voting by committee is a “meta-
modeling” technique (like ensemble) that “combines” 
multiple models by allowing them to “vote” for the winning 
classification.  It seeks to take advantage of the strengths of 
different modeling approaches while minimizing their 
drawbacks.  Due to the number of models used, detailed 
explanations of individual methods are not provided here for 
brevity, but can be found elsewhere [29,30].  
The last step was to evaluate model performance to rule 
out the possibility that statistical findings may be an artifact 
of capitalization on chance, which was performed using 10-
fold cross-validation [30]. All models were evaluated using 
multiple performance metrics, including raw predictive 
accuracy; variables related to standard ROC (receiver 
operating characteristic) analysis such as AUC (area under 
the curve) and true/false positive rates [39]; and Hand’s H 
[40].  The data mining methodology and reporting is in 
keeping with recommended guidelines [41,42], such as the 
proper construction of cross-validation, incorporation of 
feature selection within cross-validation folds, testing of 
multiple methods, and reporting of multiple metrics of 
performance, among others.  
Additionally, some of the better performing models were 
evaluated using feature selection prior to modeling (but 
within each cross-validation fold).  Feature selection is a key 
component in filtering out noisy and/or redundant variables 
from datasets and building parsimonious, explanatory 
models that retain generalizability.  Particularly of interest 
was how clinical and demographic variables would compare 
in utility versus baseline outcome measures and “early 
change” delta (baseline to third visit) for predicting final 
outcome delta.  The feature selection methods used include 
univariate filter methods (Chi-squared, Relief-F), 
multivariate subset methods (Consistency-Based –Best First 
Search, Symmetrical Uncertainty Correlation-Based Subset 
Evaluator) and wrapper-based (Rank Search employing Chi-
squared and Gain Ratio).  The advantages and disadvantages 
of these different types of feature selection are well-
addressed elsewhere [43]. For purposes of this study, feature 
selection was only performed using a Naïve Bayes wrapper 
(where variables to be included in the final model were 
chosen by first building preliminary Naïve Bayes models 
using different selections of variables and selecting the 
feature set with the highest cross-validated performance) 
[44]. 
 
C. Implementation Analysis 
A clinician survey based on TPB was sent to all 
clinicians, with about half (n=66) responding.  The survey 
included questions to assess the three domains of TPB as 
well as questions on intention to use the CDOI and years of 
experience as a practicing clinician (see Table II), each 
scored as a 4-point Likert scale.  These data were then 
combined with other EHR data such as clinician age and 
gender.  Adoption rates for each clinician (indicating the 
percent of the time the CDOI was completed when it should 
have been, not counting client opt-out skips) were calculated 
for November, 3 months after the end of the pilot and 
implementation efforts.  Additionally, average outcome 
scores (including baseline ORS and SRS and ORS delta from 
baseline to final) were collected for each clinician, based on 
the same n=714 sample described for data mining above (as 
such only about half of the clinician respondents, n=33, had 
qualifying outcomes data).  The principle questions were 1) 
how the survey results associated with the three components 
of TPB (Questions #1-9) would affect intentions (as 
indicated by Question #10), 2) if those effects would be 
mediated by other factors such as clinician experience or age, 
and 3) whether intentions were related to actual behavior 
(measured by adoption rates and outcomes).  Survey and 
associated data were analyzed via correlation analysis, t-
tests, ANOVAs, and regression analysis. 
TABLE II.  CLINICIAN PERCEPTION SURVEY 
Question # TPB Component
a
Question Text
CDOI 1 PU
I can use CDOI to better understand my client’s progress in 
therapy.
CDOI 2 PU
I believe that CDOI is a good tool for building more effective 
relationships with clients.
CDOI 3 PU
CDOI does not help me make decisions about what to do as a 
therapist.
CDOI 4 NB
I am expected to use CDOI in my clinical setting at 
Centerstone.
CDOI 5 NB
The therapists I work with, whose opinions I value support the 
use of CDOI.
CDOI 6 NB
I believe that CDOI will become a permanent tool at 
Centerstone.
CDOI 7 CB CDOI does not fit my client population.
CDOI 8 CB My CDOI training prepared me to use the tool effectively.
CDOI 9 CB
I have sufficient resources to use CDOI effectively (computers, 
space, privacy, time, etc.).
CDOI 10 INT
I intend to consistently use CDOI to enhance my effectiveness 
as a therapist.  
a. PU = Perceived Utility, NB = Normative Beliefs, CB = Control Beliefs, INT = Intentions 
 
III. RESULTS 
A. Data Analysis 
Descriptive statistics for ORS are presented in Table III, 
including baseline ORS, final ORS, and ORS final delta, 
broken out by state and by new vs. old clients.  Additionally, 
to account for a regression to the mean effect, reliable 
change (where for ORS delta, <-4 equates to “deteriorate”, 
between -4 and 4 equates to “no change”, and >4 equates to 
“improve”, as defined by Miller et al. (2006) was tested via 
Chi-Square for all clients (not excluding clients with baseline 
ORS>25) and found significant deviations from expectation 
(χ2=128.6,  p<.000, n=714) given equal categorical 
expectations.  It should be noted that approximately 52.8% 
(377/714) of clients achieved reliable improvement, which 
compares closely to Miller et al. [8] final values of 47%, 
although the reliable deterioration of 19.6% is much higher 
than their reported final 8%. Table IV shows the cross-
tabulation breakout of reliable change and clinical 
significance (defined as moving from below clinical cutoff to 
above, for ORS cutoff=25, as per Miller et al. [8]) for clients 
who started in the clinical range (baseline ORS<=25), broken 
out by old and new clients.  For the 184 new clients who fit 
this profile, nearly 46%, or approximately half, of those 
achieved both reliable improvement (reliable change = 3) 
and clinically significant change (clinical significance=1).  
Success was lower for old, existing clients, yet still 35.2% 
achieved both reliable improvement and clinically significant 
change. 
 
TABLE III.  DESCRIPTIVE STATISTICS 
N Min Max Mean Std. Dev.
bl_ors 271 2 40 21.11 8.670
final_ors 271 2 40 25.95 8.358
final_delta_ors 271 -18 30 4.85 8.412
Valid N 271
bl_ors 443 0 40 20.88 8.740
final_ors 443 0 40 24.28 9.492
final_delta_ors 443 -25 38 3.40 9.435
Valid N 443
N Min Max Mean Std. Dev.
bl_ors 461 0 40 21.43 8.811
final_ors 461 0 40 24.68 9.342
final_delta_ors 461 -25 30 3.26 8.884
Valid N 461
bl_ors 253 2 40 20.12 8.469
final_ors 253 2 40 25.35 8.667
final_delta_ors 253 -18 38 5.20 9.318
Valid N 253
0
1
State
IN
TN
New
a
 
a. 1=New, 0=Not New, see text for definition 
 
 
 
 
 
 
 
 
 
TABLE IV.  RELIABLE CHANGE VS. CLINICAL SIGNIFCANCEA 
0 1
Count 46 0 46
% of Total 15.1% .0% 15.1%
Count 64 7 71
% of Total 21.1% 2.3% 23.4%
Count 80 107 187
% of Total 26.3% 35.2% 61.5%
Count 190 114 304
% of Total 62.5% 37.5% 100.0%
0 1
Count 20 0 20
% of Total 10.9% .0% 10.9%
Count 36 1 37
% of Total 19.6% .5% 20.1%
Count 43 84 127
% of Total 23.4% 45.7% 69.0%
Count 99 85 184
% of Total 53.8% 46.2% 100.0%
Old Clients
Clinical Sign.
c
Total
Reliable 
Change
b
1
2
3
Total
Total
 New Clients
Clinical Sign.
c
Total
Reliable 
Change
b
1
2
3
 
a. Where Baseline ORS<=25 
b. For Reliable Chance, 1=Deteriorate, 2=No Change, 3=Improve 
c. For Clinical Significance, 1=yes (final ORS>25), 0=No (final ORS<=25) 
 
Modeling results to predict ORS delta final can be seen 
based on all clients (Table V) and on new clients only (Table 
VI) with and without pre-discretization (CAIM) of the 
predictor variables, sorted by AUC.  Both of these sets of 
results are based on models produced using a Naïve Bayes 
wrapper for feature selection (for reference, models of 
comparable performance were built without feature selection 
for all clients, while models consisting of new clients only 
did improve performance via feature selection).  For both all 
clients and new only, the best performing models were 
generally either Ensemble methods or Bayesian methods 
(Naïve Bayes, AODE, LBR).  For all clients, the best 
performing models produced around 70-71% accuracy and 
.76-.77 AUC.  For new clients only, the best performing 
models produced around 75-77% accuracy and .82-.83 AUC.  
These results indicate that the CDOI has the ability to serve 
as the basis for predictive models that may anticipate the 
effect of clinical treatment in terms of change over time with 
reasonable accuracy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE V.  MINING RESULTS (ALL CLIENTS) 
Model Binning Accuracy AUC TP rate FP rate H
 Naïve Bayes CAIM 70.4% 0.7718 71.5% 30.8% 0.2730
 Lazy Bayesian Rules CAIM 69.9% 0.7716 70.5% 30.8% 0.2724
 Naïve Bayes Bin Target 70.6% 0.7703 71.0% 30.0% 0.2678
 Ensemble Bin Target 70.7% 0.7699 71.4% 31.1% 0.2658
 AODE CAIM 70.9% 0.7697 72.4% 30.9% 0.2660
 Classif via Linear Reg Bin Target 70.7% 0.7683 71.3% 30.0% 0.2667
 Log Regression Bin Target 69.7% 0.7678 70.2% 30.8% 0.2658
 MP Neural Net Bin Target 69.5% 0.7665 70.4% 31.7% 0.2682
 MP Neural Net CAIM 70.6% 0.7659 72.3% 31.3% 0.2582
 Ensemble CAIM 70.7% 0.7590 71.7% 31.4% 0.2582
 Bayes Net - TAN CAIM 69.0% 0.7561 71.1% 33.1% 0.2430
 Log Regression CAIM 70.9% 0.7555 71.4% 29.8% 0.2532
 Bayes Net - K2 CAIM 68.3% 0.7517 68.9% 32.4% 0.2349
 Vote CAIM 68.5% 0.7497 69.9% 33.1% 0.2354
 K-Nearest Neighbor CAIM 69.6% 0.7451 72.2% 33.1% 0.2398
 Bayes Net - TAN Bin Target 69.3% 0.7392 69.3% 30.6% 0.2180
 Vote Bin Target 66.7% 0.7383 68.4% 35.3% 0.2140
 Bayes Net - K2 Bin Target 68.8% 0.7314 68.5% 30.9% 0.2117
 Random Forest CAIM 68.2% 0.7185 68.9% 32.7% 0.1956
 Random Forest Bin Target 65.3% 0.6979 67.5% 37.1% 0.1661
 J48 Tree CAIM 69.2% 0.6948 69.1% 31.7% 0.1992
 J48 Tree Bin Target 65.8% 0.6669 65.9% 34.2% 0.3338
 K-Nearest Neighbor Bin Target 60.8% 0.6371 63.1% 41.7% 0.0857
10X Cross-Val (partitioned)
 
TABLE VI.  MINING RESULTS (NEW CLIENTS ONLY) 
Model Binning Accuracy AUC TP rate FP rate H
 Ensemble CAIM 76.7% 0.8337 71.6% 17.6% 0.4030
 Ensemble Bin Target 76.3% 0.8250 73.2% 20.8% 0.4130
 Naïve Bayes CAIM 75.5% 0.8224 71.3% 20.2% 0.3929
 Naïve Bayes Bin Target 73.9% 0.8174 71.8% 24.3% 0.3612
 AODE CAIM 72.7% 0.8147 69.0% 23.6% 0.3708
 Lazy Bayesian Rules CAIM 73.1% 0.8141 68.4% 21.7% 0.3761
 Vote CAIM 71.9% 0.8098 68.3% 24.4% 0.3695
 MP Neural Net CAIM 72.7% 0.8064 68.8% 33.2% 0.3626
 Log Regression Bin Target 72.7% 0.8021 71.4% 26.2% 0.3494
 Classif via Linear Reg Bin Target 71.1% 0.7941 69.3% 27.3% 0.3159
 K-Nearest Neighbor CAIM 73.1% 0.7930 69.6% 23.4% 0.3233
 Vote Bin Target 72.7% 0.7895 71.4% 26.2% 0.3374
 MP Neural Net Bin Target 73.9% 0.7875 71.4% 33.9% 0.3204
 Bayes Net - K2 CAIM 70.4% 0.7827 67.2% 26.7% 0.3156
 Log Regression CAIM 66.4% 0.7791 63.6% 31.1% 0.3575
 Bayes Net - TAN Bin Target 70.8% 0.7788 68.1% 24.9% 0.3253
 Bayes Net - K2 Bin Target 68.4% 0.7724 66.4% 30.0% 0.3289
 J48 Tree Bin Target 73.1% 0.7657 67.6% 20.2% 0.2985
 Bayes Net - TAN CAIM 70.0% 0.7582 65.6% 25.4% 0.3384
 Random Forest Bin Target 69.6% 0.7492 66.7% 27.8% 0.2748
 Random Forest CAIM 68.8% 0.7411 64.6% 26.8% 0.2526
 K-Nearest Neighbor Bin Target 69.2% 0.7191 67.6% 29.6% 0.2036
 J48 Tree CAIM 70.0% 0.7140 65.0% 24.1% 0.2387
10X Cross-Val (partitioned)
 
 
An additional question was whether early ORS/SRS 
ratings (including baseline scores) were predictive of ORS 
delta final, including relative to other potential 
clinical/demographic predictors such as age, gender, 
diagnosis, and treatment modality variation.  The results can 
be seen in Table VII.  Consistently, bl_ors and 
third_delta_ors appeared as the most significant variables – 
which given the lack of a “regression to the mean” effect, is 
notable.  This finding agrees with the theory of Miller [8], 
who argues that early change from treatment (first 3 visits) 
predicts long term change (e.g. change after 3 months).  
Equivalent findings have been reported in other diseases 
such as lung cancer [45].  Additionally, bl_srs was identified 
as an important predictor whenever pre-discretization 
(CAIM) was applied. Payor_grp also appeared numerous 
times, with age, gender, diag_cat, and county occasionally 
appearing.  Quantifying the actual importance of each 
variable relative to odds ratios, where possible, is particularly 
informative.  In this regard, the third_delta_ors was by far 
the most critical variable, with an odds ratio of 11.37 ± 6.03 
(higher values more likely to show greater final ORS delta).  
Bl_ors followed, with an odds ratio of 7.86 ± 3.58, lower 
values being more likely to show greater final ORS delta.  
Both bl_srs and gender had above-1 odds ratios, though the 
lower confidence interval fell near or below 1 (the 
significance threshold).  In terms of payor_grp, it appears 
that commercial clients were more likely to obtain better 
final ORS delta values.  It is possible that this result is related 
to socio-economic status, but this interpretation warrants 
caution and further study.  There were also some differences 
in diag_cat, but they were very slight and of questionable 
importance.  It should be noted that because all clients 
received the same treatment modality during the pilot 
(outpatient therapy), we were not able to truly evaluate the 
influence of treatment modality variation, and its effect 
remains to be seen.    
TABLE VII.  FEATURE SELECTION ODDS RATIOS 
Variable Odds Ratio For >Mean Improve
bl_ors 7.86 ± 3.58 * More Likely to be lower
third_delta_ors 11.37 ± 6.03 * More Likely to be higher
gender 1.76 ± .72 * More Likely to be Male
payor_grp 1.75 ± .85 * More Likely to be Commercial, Not Sign.
bl_srs 1.74 ± .75 * More likely to be lower,Not Sign.
diag_cat 1.74 ± .79 * Mood Disorders and Subst Abuse more likely to improve, Not Sign.  
B. Implementation Analysis 
Table VIII shows the correlations between various 
components of TPB, clinician age, and behavior (adoption 
rate), as well as clinical outcomes.  Both normative beliefs 
(spearman’s rho=.45, p=.000, n=66) and perceived utility 
(spearman’s rho=.25, p=.042, n=66) significantly correlated 
with intentions.  However, there was not a significant 
relationship between intentions and eventual behavior 
(spearman’s rho= -.178).  This result represents a previously 
identified problem in which beliefs/attitudes may correlate 
with intentions, but intentions do not necessarily correlate 
with behavior [46,47].  The most likely explanation is that 
organizational requirements to collect the CDOI by 
management affected behavior in ways that mitigated the 
impact of intent.  However, one specific question (#4) that 
sought to address that issue found that older, more 
experienced clinicians were less likely to agree that they 
were expected to use the tool.  Additional regression analysis 
found that TPB components explained 30.3% of the variance 
in intent (F=8.983, p=.000, df=62) but an insignificant 
amount of actual behavior (adoption). 
 
 
 
 
 
 
 
 
 
 
 
TABLE VIII.  TPB FACTOR CORRELATIONS 
PU NB CB Intent
Adopt 
Rate age bl ors bl srs
final 
delta ors
Correlation 1.000
Sig. (2-tailed) .
N 66
Correlation .080 1.000
Sig. (2-tailed) .523 .
N 66 66
Correlation -.176 -.109 1.000
Sig. (2-tailed) .158 .383 .
N 66 66 66
Correlation .251
*
.450
** -.072 1.000
Sig. (2-tailed) .042 .000 .565 .
N 66 66 66 66
Correlation .177 .120 -.147 -.178 1.000
Sig. (2-tailed) .172 .356 .260 .169 .
N 61 61 61 61 61
Correlation -.150 -.102 -.111 -.261
*
.411
** 1.000
Sig. (2-tailed) .252 .439 .400 .044 .002 .
N 60 60 60 60 55 60
Correlation .204 -.209 -.341 -.226 -.140 -.337 1.000
Sig. (2-tailed) .254 .242 .052 .205 .470 .074 .
N 33 33 33 33 29 29 33
Correlation -.114 .061 .146 .207 -.277 -.328 -.003 1.000
Sig. (2-tailed) .526 .736 .418 .247 .146 .082 .986 .
N 33 33 33 33 29 29 33 33
Correlation -.213 -.255 .052 .118 -.120 .059 -.144 -.159 1.000
Sig. (2-tailed) .235 .151 .776 .514 .534 .761 .424 .378 .
N 33 33 33 33 29 29 33 33 33
final delta 
ors
PU
NB
CB
Intent
Adopt Rate
age
bl ors
bl srs
 
*. Correlation is significant at the 0.05 level (2-tailed) 
**. Correlation is significant at the 0.01 level (2-tailed) 
PU = Perceived Utility, NB = Normative Beliefs, CB = Control Beliefs 
 
IV. DISCUSSION 
The CDOI, a patient-reported outcome measure, was 
implemented in a large, real-world behavioral healthcare 
setting in order to evaluate previous findings from smaller 
controlled studies, such as Miller [8].  PROs provide an 
alternative window into treatment effectiveness based on 
client perception and facilitate detection of 
problems/symptoms for which there is no discernible 
measure (e.g. pain) [6].  The principle focus of this paper is 
on evaluating the utility of PROs for predictive modeling of 
outcomes in a live clinical setting.  The CDOI was found to 
be a relatively good predictor of change over time, in terms 
of predicting final outcome delta based on baseline and early 
change scores, as predicted by Miller [8] and other domains 
such as cancer [45].  Both measures of 
symptomology/functioning (ORS) and therapeutic alliance 
(SRS) contributed to this predictive capacity.  Other 
variables, such as gender, also potentially affect this 
predictive capacity.  Using new clients only, algorithms were 
constructed that could successfully predict above or below 
mean change approximately 75-77% of the time, well in 
excess of the 50% random chance.  Analysis also showed 
that the outcome deltas over time were not simply a matter of 
regression to the mean. 
Most importantly, the predictive capacity of the CDOI 
underscores the utility of direct client feedback measures 
such as PROs and their potential use as the basis for next 
generation clinical decision support (CDSS) tools and 
personalized treatment approaches.  Although many CDSS 
tools have been constructed previously using traditional 
outcome measures, PROs open a new and uncharted window 
into understanding and predicting clinical outcomes and 
treatment effectiveness. 
Implementation efforts were evaluated within the 
framework of the Theory of Planned Behavior (TPB) [21].  
Significant relationships were found between normative 
beliefs, perceived utility, and clinician intent to use the 
CDOI.  However, intention to use the CDOI did not 
necessarily translate into actual adoption behavior, a 
phenomenon previously reported elsewhere [46,47].  
Adoption behavior appeared to be impacted by clinician 
experience and age, with older, more experienced clinicians 
more likely to use the CDOI despite lower levels of 
perceived utility and intent.  Neither TPB components nor 
intent had any relation to actual clinical outcomes using the 
CDOI.  This study provides an example of a framework for 
an integrated implementation evaluation in the context of a 
larger technology or outcome implementation.  This sort of 
approach is a necessity for understanding technologies such 
as clinical decision support and outcomes measures such as 
PROs in real-world settings and the process of adoption 
[24,25] 
The study presented here was a pilot of using PROs such 
as CDOI in a large, real-world mental health setting.  Future 
directions include a larger evaluation of the CDOI in the 
context of clinical decision support for treatment 
recommendations in a real-world setting, and a comparison 
of the utility of the CDOI to more traditional measures of 
clinical outcome such PHQ9 in such settings [48].  Such an 
approach can produce individualized treatment predictions, 
as shown the examples in Figures 1 and 2 based on similar 
outcome measures, providing a clinician the probability of 
average or better treatment response across a number of 
modality combinations [13]. 
 
 
Fig. 1. Example 1 of treatment   recommendations using pre-set “service 
packages” (from [12]) 
 
 
Fig. 2. Example 2 of treatment   recommendations using pre-set “service 
packages” (from [12]) 
 
Utilizing PROs to enhance clinical decision-making 
through such data-driven CDSS approaches remains the 
long-term focus. 
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